Medicare is set to expand its coverage of GLP-1 medications, which have gained popularity for weight loss, starting in July 2026. Currently, these drugs, including Ozempic and Wegovy, are only covered for managing Type 2 diabetes, leaving beneficiaries seeking weight loss options to pay out of pocket, potentially costing nearly $1,000 per month. The upcoming changes come as part of the Better Approaches to Lifestyle and Nutrition for Comprehensive Health (BALANCE) model, which will allow some Medicare Part D plans to include GLP-1 coverage.
This development is significant for the pharmaceutical sector, particularly for companies producing GLP-1 medications, as increased accessibility could drive demand and boost sales. The decision of private insurers to adopt this coverage will also be crucial, influencing the competitive landscape in the weight loss drug market.
For financial professionals, the key takeaway is to monitor the implications of these policy changes on pharmaceutical stocks and the broader healthcare sector, especially as beneficiaries adjust their healthcare plans during the upcoming Open Enrollment Period.
Source: fool.com